Sulforaphane Clinical Trials

Size	Price	Qty
1mg	USD 147

Clinical Trials

Numerous clinical trials evaluate sulforaphane across diverse therapeutic domains, including anthracycline-related cardiotoxicity in breast cancer, major depressive disorder, schizophrenia, pre-diabetes, autism spectrum disorder, and nutritional bioavailability. Sponsored by academic and clinical research institutions such as Texas Tech University Health Sciences Center, Shanghai Mental Health Center, Chiba University, and Quadram Institute Bioscience, these studies span Early Phase 1 through Phase 4 as well as non-applicable dietary protocols. Operating across variable recruitment statuses—including recruiting, completed, terminated, and enrolling by invitation—these protocols systematically assess therapeutic efficacy and outcomes.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07040280	NOT_YET_RECRUITING	Melanoma	Eastern Cooperative Oncology Group	2025-10-31	PHASE2
NCT07652866	NOT_YET_RECRUITING	Schizophrenia Disorder	Second Xiangya Hospital of Central South University	2026-06-02
NCT03934905	RECRUITING	Anthracycline Related Cardiotoxicity in Breast Cancer	Texas Tech University Health Sciences Center	2022-06-01	PHASE1; PHASE2
NCT07668596	RECRUITING	Immunometabolism; Mitochondrial Function, Bioenergetics; Inflammation	University of British Columbia	2026-03-01
NCT07297576	RECRUITING	ALL (Acute B-Lymphoblastic Leukemia); AML (Acute Myelogenous Leukemia; MDS (Myelodysplastic Syndrome)	Institute of Hematology & Blood Diseases Hospital, China	2025-10-22
NCT03932136	ACTIVE_NOT_RECRUITING	Clinical High Risk Syndrome of Psychosis	Shanghai Jiao Tong University School of Medicine	2019-07-14	PHASE3
NCT04805957	ENROLLING_BY_INVITATION	Autism; Autism Spectrum Disorder; Autistic Disorder	Rutgers, The State University of New Jersey	2022-07-07
NCT06964659	NOT_YET_RECRUITING	Obesity and Overweight	Mª Jesús Periago	2025-07	EARLY_PHASE1
NCT06594536	NOT_YET_RECRUITING	Attention Deficit Disorder	Assistance Publique - Hôpitaux de Paris	2024-12-01
NCT07343518	NOT_YET_RECRUITING	Nutrition; Sports	University of Maia	2026-01-02
NCT02677051	ACTIVE_NOT_RECRUITING	Autism; Autistic Disorder; Autism Spectrum Disorder; Autistic Behavior	Rutgers, The State University of New Jersey	2016-02	PHASE2
NCT05408559	WITHDRAWN	Diastolic Dysfunction; Systolic Dysfunction; Diastolic Heart Failure	Texas Tech University Health Sciences Center	2022-07-01	PHASE1; PHASE2
NCT06856486	UNKNOWN	Healthy	Mª Jesús Periago	2025-03	EARLY_PHASE1
NCT07047976	WITHDRAWN	Autism Spectrum Disorder; Sulforaphane	Jian-Jun Ou	2024-09-20
NCT04848792	COMPLETED	Aging Problems	Northern Arizona University	2023-02-09
NCT05653492	ACTIVE_NOT_RECRUITING	Pediatric Kidney Disease	University of Rochester	2023-05-15	PHASE2
NCT05797506	COMPLETED	Chronic Kidney Disease Stage 3; Chronic Kidney Disease Stage 4	University of Rochester	2023-05-03	PHASE2
NCT06561893	COMPLETED	Nutrition, Healthy	University of Exeter	2024-10-01
NCT03730649	ACTIVE_NOT_RECRUITING	Skin Aging	Johns Hopkins University	2019-10-09	EARLY_PHASE1
NCT05902754	COMPLETED	Alcohol Use Disorder	Louisiana State University Health Sciences Center in New Orleans	2024-01-23
NCT03665922	COMPLETED	Prostate Cancer	University of Pittsburgh	2019-05-01
NCT04608903	ACTIVE_NOT_RECRUITING	Chronic Kidney Disease	Universidade Federal Fluminense	2021-12-01
NCT05084365	UNKNOWN	Parkinson Disease	Central South University	2021-11-28	PHASE2
NCT04364360	UNKNOWN	Non-Alcoholic Fatty Liver Disease; Obesity; Metabolic Syndrome	University of Oxford	2020-01-01
NCT05153174	COMPLETED	Chronic Kidney Disease stage3; Chronic Kidney Disease stage4	University of Rochester	2022-05-02	PHASE1
NCT03232138	COMPLETED	Lung Cancer	Jian-Min Yuan, MD	2018-01-25	PHASE2
NCT05233579	COMPLETED	Fragile X Associated Tremor/Ataxia Syndrome (Fxtas) (Diagnosis)	University of California, Davis	2021-06-25
NCT05148169	UNKNOWN	Major Depressive Disorder	Shanghai Mental Health Center	2020-01-01	PHASE4
NCT04858854	COMPLETED	Chronic Kidney Disease Stage 3B; Chronic Kidney Disease stage4; Diabetes Mellitus, Type 2	Karolinska Institutet	2021-10-10
NCT05145270	UNKNOWN	Major Depressive Disorder	Shanghai Mental Health Center	2019-11-30	PHASE4
NCT04213391	UNKNOWN	Alzheimer Disease	Second Affiliated Hospital, Zhejiang University, School of Medicine	2020-05-10
NCT04946526	COMPLETED	Sulforaphane Bioavailability	Appalachian State University	2022-06-01
NCT04521868	COMPLETED	Schizophrenia	Central South University	2020-08-31	PHASE2
NCT05224492	UNKNOWN	HIV Infections	Sunshine Specialty Health Care	2022-02-21	PHASE4
NCT03934905	Recruiting	Anthracycline Related Cardiotoxicity in Breast Cancer	Texas Tech University Health Sciences Center	2022-06-01	Phase 1\|Phase 2
NCT05146804	COMPLETED	Inflammation	Maastricht University Medical Center	2021-11-11
NCT04246905	UNKNOWN	Depressive Disorder	Central South University	2020-07-15	PHASE2
NCT04252261	UNKNOWN	Frontal Lobe Dysfunction	Xiangya Hospital of Central South University	2020-06-01	PHASE2
NCT03878368	COMPLETED	Osteoarthritis	University of East Anglia	2019-05-01
NCT03517995	WITHDRAWN	Bladder Cancer; Bladder Tumor; Urothelial Carcinoma	H. Lee Moffitt Cancer Center and Research Institute	2020-04	PHASE2
NCT05073523	Completed	Healthy	Chalmers University of Technology	2021-09-27	Not Applicable
NCT05367024	Enrolling by invitation	Pre-diabetes	Quadram Institute Bioscience\|Norfolk and Norwich University Hospitals NHS Foundation Trust	2021-09-27	Not Applicable
NCT02801448	COMPLETED	Diabetes Mellitus, Non-Insulin-Dependent	Anders Rosengren, MD PhD	2015-09	PHASE2
NCT04046653	COMPLETED	Prostate Cancer	Quadram Institute Bioscience	2019-07-03
NCT02810964	COMPLETED	Schizophrenia; Schizoaffective Disorder	Sheppard Pratt Health System	2017-02-22	PHASE2
NCT02879110	COMPLETED	Autism Spectrum Disorder	Central South University	2016-08
NCT02909959	COMPLETED	Autism Spectrum Disorder; Autistic Disorder; Neurodevelopmental Disorder; Childhood Developmental Disorders, Pervasive	University of North Carolina, Chapel Hill	2017-03-01	PHASE2
NCT02880462	COMPLETED	Schizophrenia	Central South University	2016-12-26	PHASE2
NCT03126539	TERMINATED	Aging	Johns Hopkins University	2017-09-15	PHASE2
NCT02561481	COMPLETED	Autism Spectrum Disorder	University of Massachusetts, Worcester	2015-12	PHASE1; PHASE2
NCT01950143	COMPLETED	Prostate Cancer	Quadram Institute Bioscience	2013-08
NCT02404428	TERMINATED	Prostate Cancer	Quadram Institute Bioscience	2015-02
NCT02654743	COMPLETED	Autism	University of California, San Francisco	2016-01	PHASE3
NCT01568996	COMPLETED	Atypical Nevi; Melanoma	John Kirkwood	2012-08	EARLY_PHASE1
NCT02300324	COMPLETED	Healthy	Quadram Institute Bioscience	2014-10
NCT01715480	COMPLETED	Sickle Red Blood Cell; Fetal Hemoglobin; Oxidative Stress	Duke University	2012-03
NCT01845493	COMPLETED	Asthma	University of North Carolina, Chapel Hill	2013-04	PHASE1
NCT00946309	COMPLETED	Prostate Cancer	Fred Hutchinson Cancer Center	2010-07	PHASE1; PHASE2
NCT01357070	COMPLETED	Healthy Volunteers	Imperial College London	2011-05
NCT00843167	COMPLETED	Breast Cancer; Precancerous Condition	OHSU Knight Cancer Institute	2009-08	PHASE2
NCT00982319	COMPLETED	Breast Cancer	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	2009-04	PHASE2
NCT01474993	COMPLETED	Autism	Andrew Zimmerman	2011-12	PHASE2
NCT01716858	COMPLETED	Schizophrenia	Chiba University	2012-10	PHASE2
NCT01335971	COMPLETED	COPD	Johns Hopkins University	2010-09	PHASE2
NCT01269723	COMPLETED	Smoking	University of North Carolina, Chapel Hill	2010-12
NCT01315665	COMPLETED	Cystic Fibrosis	University Hospitals Cleveland Medical Center	2011-04
NCT01228084	COMPLETED	Adenocarcinoma of the Prostate; Recurrent Prostate Cancer	OHSU Knight Cancer Institute	2010-11	PHASE2
NCT01129466	COMPLETED	Healthy Adult Volunteers	University of North Carolina, Chapel Hill	2010-05
NCT00621309	COMPLETED	Adverse Drug Interactions	University of Washington	2008-03	PHASE1

(data from https://clinicaltrials.gov, updated on 2025-06-27)

Check the Sulforaphane product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Sulforaphane acts as an inducer of nuclear factor erythroid 2-related factor 2 (Nrf2) and an inhibitor of histone deacetylase (HDAC) and NF-κB pathways, which elevates heme oxygenase-1 (HO-1) expression and suppresses reactive oxygen species (ROS) production. This signaling regulation promotes cell cycle arrest and apoptosis, mitigating oxidative damage to provide therapeutic benefits in clinical trial conditions such as anthracycline-related cardiotoxicity in breast cancer and major depressive disorder.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).